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Anticancer Organogold Complexes
Exploring the Reactivity and Biological Effects of Heteroleptic
N-Heterocyclic Carbene Gold(I)-Alkynyl Complexes
Jens Oberkofler,[a,b,c] Brech Aikman,[b] Riccardo Bonsignore,[b] Alexander Pöthig,[a]
James Platts,[b] Angela Casini,*[b,c] and Fritz E. Kühn*[a]
Abstract: With the aim to explore the effects of different orga-
nometallic ligands on the reactivity and biological properties of
a series of twelve heteroleptic AuI complexes, of general for-
mula [Au(NHC)(alkynyl)] (NHC = benzimidazolylidene or 1,3-di-
hydroimidazolylidene) were synthesized and characterized by
1H and 13C NMR and elemental analysis, and in some cases also
by X-ray diffraction. The compounds were all stable in H2O/
DMSO as established by NMR spectroscopy, while they could
react with model thiols (EtSH) in the presence of water to un-
dergo ligand-substitution reactions. 1H NMR experiments
showed that dissociation of the more labile alkynyl ligand was
possible for all compounds, while in the case of the benzimid-
azolylidene series also dissociation of the NHC ligand could be
Introduction
As the World Health Organization states in its report, approxi-
mately 14 million new cases of cancer and 8 million cancer-
related deaths were registered in the year 2012 alone, both
numbers rising steadily and underpinning the urgency of devel-
opment and improvement of new anticancer drugs.[1] The PtII
complex cisplatin was approved by the FDA in 1978 and is still
widely used in clinics against cancer, together with a number
of analogues (e.g. carboplatin, oxaliplatin etc.).[2] Despite its suc-
cess, the demand for new pharmaceuticals, including metal-
based compounds, is on the rise since platinum compounds
can cause severe side effects as well as build up resistances. In
this context, the design of gold(I) and gold(III) compounds has
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observed. DFT calculations suggest that, depending on the
steric hindrance exerted by both the NHC wingtip groups and
the alkynyl substituents, the reaction can proceed either via a
π-stabilized intermediate or with the alkynyl ligand remaining
purely σ-coordinated to the AuI center until completely dissoci-
ated. The most stable compounds in PBS buffer (pH 7.4), as
assessed by UV-Visible spectrophotometry, were further investi-
gated for their ability to stabilize G4 DNA by FRET DNA melting
assay, showing only moderate activity. Moreover, two deriva-
tives were tested in vitro for their anticancer activities in three
different human cancer cell lines and showed cytotoxicity in
the low micromolar range.
attracted great attention as an alternative to the well-estab-
lished platinum drugs.[3] While AuI complexes generally feature
a linear geometry, with the gold center coordinated by two
ligands, AuIII compounds prefer a square-planar coordination
and are isoelectronic (d8) to the aforementioned PtII com-
pounds.[4]
The stabilization of the oxidation states +I and +III in aque-
ous environment plays a key role in the design of biologically
active gold compounds. In recent years N-heterocyclic carbenes
(NHCs) have emerged as a particularly valuable family of li-
gands for the design of novel anticancer drugs.[5] The high
stability of the metal–NHC bond leads to a lower risk of
metabolization/speciation of the biologically active compound.
Furthermore, the modification of the NHC ligand is significantly
less challenging than in the case of phosphines or other types
of ligands. Moreover, steric and electronic properties of the re-
sulting metal NHC complexes are easily tunable and allow
modulation of the compounds' solubility, lipophilicity, reactiv-
ity, stability and targeting properties.[6–9]
In general, gold compounds have lower affinity for nucleic
acid binding with respect to PtII compounds, with a few excep-
tions. Instead, they primarily target proteins and enzymes, in-
cluding the seleno-protein thioredoxin reductase (TrxR),[10] zinc
finger proteins,[11] and the water and glycerol channels aqua-
porins,[12] among others.[13] In all cases, gold complexes have
high affinity for binding to sulfur donors in proteins, including
thiols of cysteine residues. Alternatively, our group has recently
shown that some cationic bis-NHC AuI compounds, endowed
with high stability in aqueous environment, can target and sta-
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bilize DNA secondary structures of pharmacological relevance,
G-quadruplexes (G4s),[14] via a mechanism where no covalent,
but rather π–π stacking and possibly electrostatic interactions
take place between the compound and the nucleobases.[15]
To date, numerous AuI NHC compounds with anticancer ac-
tivities in the low micro- and nanomolar range have been re-
ported.[6,7,9] Most compounds have been designed as neutral
mono- {[Au(NHC)L], L = phosphine, thiol, etc.} or cationic bis-
carbene {[Au(NHC)2]+} complexes, with modifications occurring
at either of the three aforementioned positions (wingtip, back-
bone, ancillary ligand), with imidazole and benzimidazole as a
core structure.[6] In this context, some of us reported on the
anticancer properties of a heteroleptic NHC-Au-alkynyl complex
featuring a tert-butylacetylene moiety as ancillary ligand.[16] The
compound showed cytotoxicity in cancer cells in vitro, while
being scarcely toxic in healthy rat kidney tissues ex vivo. More
recently, we comparatively evaluated two novel families of AuI
bis-N-heterocyclic carbene and mixed NHC-alkynyl organome-
tallics, featuring xanthine ligands, with respect to their stability
in aqueous environment, G-quadruplex stabilizing effect and
cytotoxicity.[17]
This work focuses on the synthesis, biological evaluation and
systematic study of the reactivity of a new series of heteroleptic
NHC-AuI-alkynyl compounds by variation of the carbene core,
the nitrogen wingtips, as well as the alkynyl ancillary ligand, to
ensure different electronic and steric properties of the resulting
AuI compounds. Thus, the reactivity of the compounds with
model thiols, as relevant intracellular nucleophiles, was investi-
gated by 1H NMR spectroscopy and DFT methods, while their
stability in buffered solution was also preliminarily studied by
UV-Visible spectroscopy. To elucidate the compounds' possible
interaction with nucleic acids as relevant pharmacological tar-
gets, suitable AuI complexes were additionally examined for
Figure 1. ORTEP style representation of 2, 5, 6, 8 and 9 with ellipsoids shown at a 50 % probability level. Hydrogen atoms are omitted for clarity.
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their G4 DNA stabilization capabilities by Förster Resonance En-
ergy Transfer (FRET) DNA melting assay. Finally, the antiprolifer-
ative properties of a few derivatives were tested in human can-
cer cells in vitro.
Results and Discussion
Synthesis and Characterization
In this work, a series of AuI NHC complexes featuring alkynyl
groups as ancillary ligands have been synthesized and charac-
terized by different methods. Scheme 1 shows the general syn-
thetic approach to NHC-AuI-alkynyl compounds 1–12. In the
series, complexes 1–6 feature the benzimidazole (BzImi) scaf-
fold, while complexes 7–12 the imidazolium (Imi) one. Com-
pounds 1,[18] 4,[19] 7,[20] 10,[21] 11[22] and 12[22] have already
been reported, and the synthetic procedures have been
adapted here as necessary. In a first step, (benz)imidazolium
Scheme 1. General synthetic approach to NHC-AuI-alkynyl compounds 1–12.
BzImi= benzimidazolylidene; Imi = 1,3-dihydroimidazolylidene.
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salts were converted to NHC-AuI-Cl complexes by transmetala-
tion via the corresponding silver analogue. In a second step, a
base (NaOH or KOtBu) was used to deprotonate the alkyne
which then undergoes a ligand exchange reaction with chloride
to give the desired NHC-AuI-alkynyl compounds 1–12 in moder-
ate to good yields (27–90 %). The compounds were character-
ized by 1H NMR and 13C NMR spectroscopy, elemental analysis
(EA) and single-crystal X-ray structure analysis (SC–XRD, com-
pounds 2, 5, 6, 8 and 9).
All of the obtained X-ray structures display a classical linear,
two-coordinated AuI center as shown in Figure 1. The alkynyl
substituents of 2, 5 and 9 are tilted out of plane when com-
pared to the NHC ligand with torsion angles of 3.89° (2), 71.41°
(5) and 63.58° (8), respectively. A summary of selected bond
lengths and angles can be found in Table 1, while full datasets
are reported in Table S2 in the supplementary material.
The C(1)–Au bond lengths are in the range of 1.985(4)-
2.023(5) Å and the Au–C(sp) bond lengths between 1.987(5)-
2.058(4) Å. The C(1)–Au–C(sp) angles are in the range of
172.81(15) - 179.4(2)°, deviating from an ideal 180° angle possi-
bly due to crystal packing effects. The crystal lattice of com-
pounds 5 and 6 show additional intermolecular Au···Au interac-
tions in the range of 3.211 Å and 3.722 Å, respectively. Bond
lengths, angles and intermolecular Au interactions are in ac-
cordance with previously reported structures.[19]
Figure 2. 1H NMR spectra in [D6]DMSO of compound 6 alone and in the presence of EtSH, recorded over time. A shows the whole spectra, B and C show
selected cutouts between 4.90–10.0 ppm and 1.53–1.80 ppm, respectively. The spectrum of tBu-acetylene and BzImi+ are shown for comparison (panels B
and C). The color code in the NMR spectra matches the signals of the products depicted on the left.
Eur. J. Inorg. Chem. 0000, 0–0 www.eurjic.org © 0000 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim3
Table 1. Selected bond lengths and angles obtained by SC XRD.
Compound C(1)–Au [Å] Au–C(sp) [Å] C(1)–Au–C(sp) [°] Au···Au [Å]
2 2.023(5) 1.987(5) 179.4(2) 6.878
5 1.985(4) 2.058(4) 172.81(15) 3.211
6 1.997(3) 2.022(3) 173.75(14) 3.722
8 2.017(4) 1.987(3) 177.86(16) 7.234
9 2.009(2) 1.987(2) 177.12(18) 6.923
Reactivity with Thiols
As mentioned above, AuI NHC complexes are likely to react with
thiol groups of proteins, found in cysteine residues, which may
be responsible for their cytotoxicity as well as for off-target ef-
fects (e.g. deactivation by intracellular thiols or binding to se-
rum albumin). Therefore, the ligand exchange reaction of NHC-
AuI-alkynyl compounds in the presence of model thiols was in-
vestigated by NMR spectroscopy and density functional theory
(DFT) methods.
Initially, all compounds were studied for their stability in the
presence of water (see Fig. S25–S36). Each compound was dis-
solved in [D6]DMSO/D2O (80:20) and its stability monitored by
1H NMR spectroscopy. The obtained results show that all com-
pounds are stable with respect to hydrolysis over the course of
two (1–6) or even nine days (7–12). Next, the reactivity of AuI
complexes with an excess of ethanethiol (EtSH), used as model
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Figure 3. 1H NMR spectra in [D6]DMSO of compound 12 alone and in the presence of EtSH, recorded over time. Panel A shows the whole spectra, B and C
show selected cutouts between 7.30–8.00 ppm and 0.85–3.00 ppm, respectively. The spectrum of tBu-acetylene is shown for comparison (panels B and C).
The color code in the NMR spectra matches the signals of the products depicted on the left.
thiol, was monitored by 1H NMR spectroscopy in [D6]DMSO (Fig-
ure 2 and Figure 3 and Fig. S37–S45). Concerning the benzimid-
azolylidene series, Figure 2 shows representative spectra for
compound 6 recorded before and after addition of EtSH over
two days. After 24 h, the aromatic signals experience a small
downfield shift (from 7.93 and 7.42 ppm to 7.94 and 7.43 ppm,
respectively), while the CH-signal of the isopropyl group un-
dergo an upfield shift (from 5.38 to 5.36 ppm) and the CH3-
signal of the isopropyl group a downfield shift (from 1.69 to
1.72 ppm). Additional signals are observed in the spectrum of
6 recorded after 2 days, which were attributed to possible gold
catalyzed alkyne activation.[23] Compounds 2 and 3 (Me-BzImi)
feature similar spectral changes over time (Fig. S38 and S39), as
well compounds 4 and 5 (Fig. S40 and S41), which all share the
same benzimidazolylidene NHC ligand (iPr-BzImi) as 6. These
variations are attributed to the formation of the NHC-AuI-SEt
adduct (Scheme 2), and are in line with previous studies on the
reactivity of Au NHCs with model thiols.[16,24] Instead, complex
1 behaves differently and undergoes the loss of the BzImi li-
gand already after 5 h (Figure S37).
Furthermore, in the case of 6, the signal of the tert-butylacet-
ylene group (1.16 ppm) disappears within 24 h (Figure 2). In
concomitance, signals of free alkyne appear (at 1.18 and
2.85 ppm), confirming the displacement of the alkynyl ligand,
leading to the formation of NHC-Au–SEt and free alkyne. After
two days, a second set of signals can be observed (at 9.75,
8.14, 7.69, 5.06 and 1.64 ppm) matching the signals of the free
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Scheme 2. Reactivity of BzImi-AuI-alkynyl compounds 2–6 in the presence of
the soft Lewis base EtSH. For the Imi-AuI-alkynyl complexes (7–12), the reac-
tion stops after Step I.
benzimidazolium salt, indicating the displacement of the NHC
ligand possibly by a second equivalent of EtSH. This is also ob-
served in the spectra of complexes 2–5 (Fig. S38–S41).
In all cases, we exclude formation of cationic bis-carbene
products which would give rise to charcateristic NMR signals of
the benzimidazole aromatic backbone in the range of 7.0–
8.0 ppm. As representative examples, we report the spectra of
the [Au(Me-BzImi)2]+ and [Au(iPr-BzImi)2]+ derivatives in Figures
S37 and S40.
Concerning the 1,3-dihydroimidazolylidene series (7–12),
Figure 3 shows representative spectra for compound 12 re-
corded before and after addition of EtSH over a period of eight
days. Only after this time, a second set of signals can be ob-
served (7.89 ppm, 7.53 ppm, 7.36 ppm, 1.26 ppm, 1.19 ppm)
matching the signals in the 1H NMR spectra of compounds 10
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and 11 (Fig. S44 and S45), which all share the same (Dipp)Imi-
NHC motif. Compounds 7 and 9 feature similar spectral changes
after 2 and 8 days (Fig. S42 and S43). In concomitance, signals
of free tert-butylacetylene can be observed (2.84 ppm,
1.18 ppm), indicating the displacement of the alkynyl ligand
upon formation of a NHC-AuI-SEt complex. Previous studies by
our group showed that 12 undergoes a similar reaction with
DL-homocysteine, where the alkynyl ligand is displaced by the
thiol nucleophile. In the latter case, however, the reaction pro-
ceeds faster and is completed within 24 h.[16]
In general, all the investigated AuI compounds, except for
compound 1, show a similar reaction pattern, where the thiol
displaces the more labile alkynyl ligand (Step I, Scheme 2). Thus,
compounds 2–6 show full conversion to the corresponding
NHC-AuI-SEt compound after one (2, 3, 5, 6) or two days (4).
For compounds 2–6, a second reaction step (Step II, Scheme 2)
could also be observed involving the displacement of the more
stable NHC ligand. Compounds sharing the Imi type NHC ligand
show different behaviors concerning their stability. While 7 and
10 (both sharing the phenylacetylene ligand) show full conver-
sion to the corresponding NHC-AuI-SEt after two days (7) and
one day (10), respectively, compound 11 already reacts remark-
ably slower, with the reaction being completed only after four
days. Interestingly, especially compounds 9 and 12 show high
stability against EtSH. For compound 9 the reaction to the cor-
responding NHC-AuI-SEt takes eight days, while the reaction of
compound 12 is not completed even after this time. The reac-
tivity of compound 8 with EtSH could not be determined by 1H
NMR spectroscopy due to its scarce solubility in [D6]DMSO. In
Figure 4. Mechanism of the reaction of compounds 3 (A) and 12 (B) with MeSH. Molecular representation of TS1, I and TS2 (C).
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general, the bulkier the wingtip groups of the compound and
the alkynyl ligand, the slower its reaction with EtSH.
It has to be noted that both the EtSH and the [D6]DMSO
used in the experiments contained traces of water. Therefore,
in order to achieve a better understanding of the role of water
molecules during the mechanism, reactivity studies with com-
pound 6 were carried out with dry EtSH in dry [D6]DMSO. In
this case, the reaction proceeds only very slowly (see Fig. S46).
While the displacement of the alkynyl ligand is already com-
pleted after one day in the presence of water, almost no reac-
tion takes place in the absence of water after two days and
only a 30 % conversion can be observed after eight days.
To explore the reactivity of the AuI complexes with thiols and
the underlying mechanism at a molecular level, DFT calcula-
tions were conducted on compounds 3 and 12, as representa-
tive members of the two series, reacting with methanethiol
(MeSH). One molecule of water was included in the mechanism
as shown in Figure 4. In an initial step, compound 3 undergoes
the concomitant activation of the alkynyl bond by the AuI ion
and the nucleophilic attack to the AuI center by the thiol, while
the water molecule acts as a proton shuttle to transfer a proton
from the thiol group to the alkynyl ligand to give intermediate
I (Figure 4A).
This process goes via a trigonal planar transition state TS1
with an activation energy of 108.2 kJ/mol. Few examples of
neutral, trigonal-planar coordinated AuI compounds, where an
alkynyl ligand is π coordinated to the gold center, have been
reported before.[25] The activation energies and geometries of
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the transition states are in accordance to previously reported
DFT studies on similar NHC-AuI-Cl complexes with protein tar-
gets.[26] In a second step, compound 3 undergoes complete
dissociation of the alkynyl ligand and formation of the NHC-
AuI-SMe complex via another trigonal planar transition state
TS2, with a very small activation barrier of 2.28 kJ/mol.
In contrast, compound 12 proceeds towards the formation
of NHC-AuI-SEt without an intermediate via a trigonal planar
transition state (TS1, Figure 4B), while showing a higher activa-
tion barrier of 128.77 kJ/mol. While the Au–C(sp) and the Au–S
bond lengths of the two transition states are comparable
(2.208 Å and 3.175 Å for compound 3, and 2.156 Å and 2.991 Å
for compound 12), the Au–C(tBu) bond length and the
Au–C(sp)–C(tBu) bond angle differ greatly (2.406 Å and 83.236°
for compound 3, and 3.127 Å and 132.470° for compound 12).
The difference in activation energy can, therefore, be explained
by the difference in stabilization of the transition states. While
the transition state of compound 3 is not sterically hindered
and can undergo a favorable π-stabilization, the alkynyl ligand
of compound 12 remains purely σ coordinated to the AuI cen-
ter, due to the steric hindrance due to the respective NHC and
alkynyl ligands (Figure 5). The higher energy barrier of com-
pound 12 for the dissociation of the alkynyl ligand is in agree-
ment with the experimental NMR data.
Stability in Buffered Solution
Compounds 1–12 were tested for their stability in a DMSO/PBS
(pH 7.4, DMSO <2 %) solution by UV-Vis spectroscopy over 4 h
at room temperature. The resulting absorption spectra feature
bands in the range of 250–350 nm due to the organic ligands
which undergo hypochromic shifts over time (Fig. S47–S48). A
general trend of stability can be observed regarding the possi-
ble hydrolysis of the alkynyl ligands in the first hours. Specifi-
cally, the rate of compounds' degradation/hydrolysis seems to
be more influenced by the type of alkynyl group than by the
NHC scaffold (BzImi vs. Imi). The phenyl-substituted AuI com-
pounds (1, 4, 7, 10) are the least stable in buffer, undergoing
extensive decomposition within the first hour, possibly followed
by precipitation, as shown by the progressive disappearance of
the main absorption bands. The naphthyl-substituted AuI com-
pounds (2, 5, 8) are slightly more stable but still prone to hy-
drolysis/precipitation within 4 h. Finally, the tert-butyl-substi-
tuted AuI compounds (3, 6, 9) are the most stable and only the
imidazole-based compound 9 undergoes extensive reduction
of the absorption bands after 4 h incubation (Fig. S48). An ex-
ception to this general trend is constituted by the tert-butyl-
substituted AuI complex (12), showing marked hypochromic
spectral changes within 4 h.
FRET DNA Melting Assay
Afterwards, the BzImi-based compounds 2–6 were selected for
FRET DNA melting analysis due to their extended π system,
which make them possible candidates for the stabilization of
G4 DNA. In details, hTelo and C-KIT1 were chosen as models of
telomeric and promoter G4 DNA, respectively. As shown in Fig-
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Figure 5. Transition states of compounds 3 and 12 and their spacefill style
representations.
ure 6 and Table S1, only compound 3 shows a significant G4
stabilizing effect, stabilizing hTelo by 3.51 (±0.08) °C and C-KIT1
by 7.00 (±0.05) °C. While the compound is less effective than
the benchmark bis-NHC AuI complex [Au(9-methylcaffein-8-
ylidene)2]+ (ΔTm = 13.26±0.60 and 17.44±0.85 °C for hTelo and
C-KIT1, respectively) it is certainly more effective than the previ-
ously reported mono-caffeine AuI alkynyl analogues which
showed no G4 stabilization.[17]
Antiproliferative Activity
Finally, two of the new compounds (3 and 9) were tested for
their antiproliferative effects against human cancer cells in vitro,
using the classical MTT assay (see Experimental for details). The
preliminary data are compiled in Table 2 in comparison to the
values previously reported for compound 12.[16] The results
show that the compounds are moderately active, with EC50 val-
ues in the low μM range, although having a certain selectivity
with respect to the various cancer cell lines. For example, com-
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Figure 6. Representative FRET DNA melting profiles of 0.2 μM hTelo (A) and C-KIT1 (B) G4-DNA solutions in 60 mM potassium cacodylate (pH = 7.4) in presence
of 5 equiv. of selected AuI NHC compounds 1–3; (C) ΔTm [°C] of hTelo and C-KIT1 G4-DNA solutions in 60 mM potassium cacodylate (pH = 7.4) in presence of
5 equiv. of 1–3. Data are shown as mean ± SEM of three independent experiments.
pound 9 is particularly active against the melanoma A375 cell
line (EC50 = 3.4 ± 0.5 μM), comparable to cisplatin.
Table 2. EC50 values of heteroleptic NHC-AuI-alkynyl complexes in human
cancer cell lines, in comparison to cisplatin, after 72 h incubation.[a]
Compound SKOV-3 (ovarian) MCF-7 (breast) A375 (skin)
3 13 ± 3 7.6 ± 0.8 12 ± 4
9 12 ± 2 7.1 ± 0.9 3.4 ± 0.5
12 n.d. 6 ± 2[b] 10 ± 1[b]
cisplatin 13.2 ± 2.4 12 ± 2 3.7 ± 0.9
[a] The reported EC50 values were calculated using a nonlinear fitting of
log[concentration] vs. response and are presented as a mean (± SD) of at
least three independent experiments; n.d.: not determined. [b] Data taken
from ref.[16]
Conclusions
In this work, a small library of NHC-AuI-alkynyl complexes with
different substituents on the NHC scaffold as well as on the
alkynyl ligand have been synthesized and fully characterized by
different methods. Stability studies show that all compounds
are stable in a mixture DMSO/H2O as evidenced by 1H NMR
spectroscopy, but react in the presence of EtSH, leading in most
cases, with the exception of compound 1, to the nucleophilic
substitution of the alkynyl ligand by the thiol group (Step I). Of
note, the BzImi-AuI-alkynyl complexes, upon EtSH binding, can
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also undergo the detachment of the NHC ligand over time (Step
II). It is also worth noting that all the aforementioned ligand-
substitution reactions are relatively slow in the applied experi-
mental conditions (i.e. days), and that the presence of H2O is
necessary to initiate the nucleophilic substitution by EtSH.
DFT calculations led to a consistent mechanism for the title
reaction (Step I) and the optimized geometries reveal that the
transition state of the AuI complexes reacting with EtSH exhibits
trigonal planar configuration, in accordance with previous stud-
ies on bis-NHC AuI complexes and cysteine-thiols.[27] In the case
of the BzImi series, a trigonal reaction intermediate I is also
identified, which can then easily progress towards the final
Bzi-AuI-SEt product.
Overall, NMR studies and DFT calculations suggest that the
stability of the compounds with respect to EtSH is primarily
influenced by: i) the type of NHC scaffold (BzImi vs. Imi), ii) the
type of NHC wingtip groups and iii) the substitution at the alk-
ynyl ligand. Specifically, the BzImi-based complexes (1–6) show
full conversion into BzImi-AuI-SEt adducts after one or two days
independently on the type of NHC or alkynyl derivatization. In-
stead, the reactivity of the Imi-based compounds with EtSH va-
ries depending on the steric hindrance between the NHC wing-
tip groups and the alkynyl substituents, during the transition
state of the reaction, with 9 [(Mes)-AuI-(tert-butylacetylene)]
and 12 [(Dipp)-AuI-(tert-butylacetylene)] being the most stable
for at least 8 days.
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All compounds were further tested for their stability in PBS
(pH 7.4) to mimic the biological conditions. In these conditions,
the compounds' possible decomposition/precipitation appears
to be favored with respect to the aforementioned NMR studies,
occurring in few hours. Moreover, the stability of the com-
pounds in buffer seems to be more influenced by the type of
alkynyl ligand rather than by the NHC scaffold. A general stabil-
ity trend (with respect to the alkynyl substitution) of phenyl
< naphthyl < tBu can be observed, with tBu being the most
stable.
In conclusion, the mechanism of reactivity of heteroleptic
NHC-AuI-alkynyl compounds is extremely complex and further
studies are necessary to be able to draw complete structure-
activity relationships and to understand the role of water mole-
cules and buffer components in the different possible path-
ways.
Finally, concerning the cytotoxic activity, preliminary results
show that compounds 3 and 9 are only moderately active in
vitro against all the tested cancer cell lines, comparable to cis-
platin. The moderate cytotoxic effect is in line with the com-
pounds' scarce reactivity with DNA G-quadruplexes and model
thiols. Together with previously reported compound 12, these
results are among the few examples of heteroleptic NHC-AuI-
alkynyl compounds showing antiproliferative effects. In the fu-
ture, other families of AuI NHC carbenes should be studied for
their biological effects, including based on triazole and tetraz-
ole scaffolds, which are still rare in the literature,[28] but en-
dowed with different reactivity profiles.
Experimental Section
General Remarks: Reactions were carried out without taking spe-
cial precautions to exclude air and water. All chemicals were used
as received. Solvents were distilled prior to use. NHC-AuI-Cl com-
plexes were synthesized by previously reported routes: Chloro(1,3-
diisopropylbenzimidazolin-2-ylidene)gold(I) was synthesized as de-
scribed by Jothibasu et al.[29] Chloro-(N,N-dimethylbenzimidazol-2-
ylidene)gold(I) was synthesized as described by Rodríguez-Castillo
et al.[30] Au(Dipp)Cl and Au(Mes)Cl were synthesized as described
by Collado et al.[31] The synthesis for compounds 1–6 was adapted
from Garg et al.[19] The synthesis for compounds 7–12 was adapted
from Gao et al.[32] 1H and 13C NMR spectra were recorded on a
Bruker AV400HD or a Bruker AV 500cryo spectrometer. 1H and 13C
NMR spectra were referenced to the residual solvent signals.[33] Ele-
mental analyses were done by the Microanalytical Laboratory at the
Technical University of Munich.
The general procedure for the synthesis of benzimidazolyl-AuI-alk-
ynyl complexes 1–6 is shown in Scheme 3.
Scheme 3. General procedure for the synthesis of complexes 1–6.
The corresponding alkyne and NaOH were dissolved in MeOH and
heated to reflux for 15 minutes. The corresponding NHC-AuI-Cl
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complex was added and heated to reflux for the time indicated.
The suspension was evaporated to dryness, dissolved in DCM and
extracted three times with water. The combined organic phases
were dried with Na2SO4, filtered and the solvents evaporated to
dryness. Compounds 3 and 5 needed additional purification steps,
which are indicated at the corresponding entries.
(Me)BzImi-AuI-(phenylethynyl) (1): A mixture of 17.4 μL phenyl-
acetylene (16.9 mg, 158 μmol, 1 equiv.), 44.4 mg of NaOH
(1.11 mmol, 7 equiv.) and 50.0 mg of chloro-(N,N-dimethylbenzimid-
azol-2-ylidene)gold(I) (132 μmol, 1 equiv.) was dissolved in 20 mL
of MeOH and refluxed for three hours. Compound 1 was obtained
as a white solid (52.8 mg, 119 μmol, 90 %). 1H NMR (400 MHz,
[D6]DMSO): δ (ppm) = 7.76 (dd, 3JH-H = 6.1 Hz, 4J = 3.2 Hz, 2H;
Har(BzImi)), 7.49 (dd, 3JH-H = 6.1 Hz, 3.1 Hz, 2H; Har(BzImi)), 7.32–7.24
(m, 4H; Har(Ph)), 7.24–7.17 (m, 1H; Har(Ph)), 4.03 (s, 6H, HMe); 13C NMR
(101 MHz, [D6]DMSO): δ (ppm) = 193.0, 133.6, 133.4, 131.2, 128.2,
126.2, 126.1, 124.2, 111.8, 104.2, 34.6; elemental analysis calcd. (%)
for C17H15N2Au: C 45.96, H 3.40 N 6.31; found C 46.04 H 3.43 N 6.03.
(Me)BzImi-AuI-(naphthylethynyl) (2): A mixture of 26.3 μL naph-
thylacetylene (28.1 mg, 185 μmol, 1 equiv.), 51.8 mg of NaOH
(1.29 mmol, 7 equiv.) and 70.0 mg of chloro-(N,N-dimethylbenzimid-
azol-2-ylidene)gold(I) (185 μmol, 1 equiv.) was dissolved in 15 mL
of MeOH and refluxed for four hours. Compound 2 was obtained
as a slightly yellow solid (91.4 mg, 159 μmol, 86 %). Single crystals
suitable for X-ray diffraction were obtained by slow diffusion of
pentane into a solution of compound 2 in acetone. 1H NMR
(400 MHz, [D6]DMSO): δ (ppm) = 8.45 (d, 3JH-H = 8.2 Hz, 1H; Hnaph),
7.91 (d, 3JH-H = 7.2 Hz, 1H, Hnaph), 7.81–7.74 (m, 3H, Hnaph/Har(BzImi)),
7.61–7.47 (m, 5H, Hnaph/Har(BzImi)), 7.43 (dd, 3JH-H = 8.2 Hz, 7.2 Hz
1H, Hnaph), 4.07 (s, 6H, HMe); 13C NMR (101 MHz, [D6]DMSO): δ
(ppm) = 190.5, 133.4, 133.3, 132.9, 132.1, 129.2, 128.2, 126.5, 126.3,
126.2, 125.7, 124.0, 123.9, 113.3, 102.0, 52.9, 21.9; elemental analysis
calcd. (%) for C21H17N2Au: C 51.02, H 3.47 N 5.67; found C 50.83 H
3.47 N 5.42.
(Me)BzImi-AuI-(tert-butylethynyl) (3): A mixture of 130 μL tert-
butylacetylene (86.8 mg, 1.06 mmol, 5 equiv.), 59.2 mg of NaOH
(1.48 mmol, 7 equiv.) and 80.0 mg of chloro-(N,N-dimethylbenzimid-
azol-2-ylidene)gold(I) (211 μmol, 1 equiv.) was dissolved in 15 mL
of MeOH and refluxed for four hours. As a last purification step,
the compound was dissolved in DCM and filtered through basic
aluminium oxide. The filtrate was evaporated to dryness and com-
pound 3 was obtained as a white solid (89.7 mg, 123 μmol, 58 %).
1H NMR (400 MHz, [D6]DMSO): δ (ppm) = 7.73 (dd, 3JH-H = 6.1 Hz,
4JH-H = 3.1 Hz, 2H, Har(BzImi)), 7.47 (dd, 3JH-H = 6.1 Hz, 3JH-H = 3.1 Hz,
2H, Har(BzImi)), 3.98 (s, 6H, HMe(BzImi)), 1.15 (s, 9H, HMe(alkynyl)). 13C NMR
(101 MHz, [D6]DMSO): δ (ppm) = 194.0, 133.5, 124.1, 117.4, 112.9,
111.7, 99.5, 34.5, 32.2, 27.6; elemental analysis calcd. (%) for
C15H19N2Au: C 42.46, H 4.51 N 6.60; found C 42.15 H 4.47 N 6.58.
(iPr)BzImi-AuI-(phenylethynyl) (4): A mixture of 25.3 μL phenyl-
acetylene (23.5 mg, 230 μmol, 1 equiv.), 64.4 mg of NaOH
(1.61 mmol, 7 equiv.) and 100.0 mg of chloro(1,3-diisopropylbenzi-
midazolin-2-ylidene)gold(I) (230 μmol, 1 equiv.) was dissolved in
20 mL of MeOH and refluxed for three hours. Compound 4 was
obtained as a white solid (63.1 mg, 127 μmol, 90 %). 1H NMR
(400 MHz, [D6]DMSO): δ (ppm) = 7.96 (dd, 3JH-H = 6.2 Hz, 4JH-H =
3.2 Hz, 2H, Har(BzImi)), 7.43 (dd, 3JH-H = 6.2 Hz, 4JH-H = 3.2 Hz, 2H,
Har(BzImi)), 7.34–7.24 (m, 4H, HPh), 7.22–7.16 (m, 1H, HPh), 5.38 (hept,
3JH-H = 7.0 Hz, 2H, HCH), 1.72 (d, 3JH-H = 7.0, 12H, HMe). 13C NMR
(101 MHz, [D6]DMSO): δ (ppm) = 190.5, 132.6, 131.6, 131.2, 128.2,
126.2, 126.1, 124.0, 113.4, 104.5, 52.7, 21.9. elemental analysis calcd.
(%) for C21H23N2Au: C 50.41, H 4.63 N 5.60; found C 50.53 H 4.72 N
5.54.
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(iPr)BzImi-AuI-(naphthylethynyl) (5): A mixture of 22.9 μL
naphthylacetylene (24.5 mg, 161 μmol, 1 equiv.), 45.1 mg of NaOH
(1.13 mmol, 7 equiv.) and 70.0 mg of chloro(1,3-diisopropylbenz-
imidazolin-2-ylidene)gold(I) (161 μmol, 1 equiv.) was dissolved in
15 mL of MeOH and refluxed for five hours. As a last purification
step, the compound was dissolved in DCM and fractionally precipi-
tated with pentane. The precipitate was washed with pentane
(3×3 mL) and the solvents evaporated to dryness. Compound 5 was
obtained as an off-white solid (49.8 mg, 90.2 μmol, 56 %). Single
crystals suitable for X-ray diffraction were obtained by layering
pentane on top of a solution of compound 5 in DCM. 1H NMR
(400 MHz, CDCl3): δ (ppm) = 8.69 (d, 3JH-H = 7.5 Hz, 1H, HNaph), 7.80
(d, 3JH-H = 8.1 Hz, 1H, HNaph), 7.75 (dd, 3JH-H = 7.0 Hz, 4JH-H = 1.3 Hz,
1H, HNaph), 7.70 (dd, 3JH-H = 7.0 Hz, 4JH-H = 1.3 Hz, 1H, HNaph), 7.66
(dd, 3JH-H = 6.2, 4JH-H = 3.2 Hz, 2H, Har(BzImi)), 7.54 (ddd, 3JH-H = 8.1,
6.9 Hz, 4JH-H = 1.3 Hz, 1H, HNaph), 7.47 (ddd, 4JH-H = 8.1, 6.9 Hz,
4JH-H = 1.3 Hz, 1H, HNaph), 7.39 (d, 3JH-H = 7.5 Hz, 1H, HNaph), 7.36
(dd, 3JH-H = 6.2 Hz, 4JH-H = 3.2 Hz, 2H, Har(BzImi)), 5.64 (hept, 3JH-H =
7.0 Hz, 2H, HCH), 1.76 (d, 3JH-H = 7.0 Hz, 12H, HMe). 13C NMR
(101 MHz, CDCl3): δ (ppm) = 192.0, 134.0, 133.2, 133.0, 132.6, 130.4,
127.8, 127.4, 126.6, 125.8, 125.7, 125.2, 123.4, 113.1, 103.1, 53.9, 21.7;
elemental analysis calcd. (%) for C25H25N2Au: C 54.55, H 4.58 N 5.09;
found C 54.14 H 4.63 N 5.07.
(iPr)BzImi-AuI-(tert-butylethynyl) (6): A mixture of 99.2 μL tert-
butylacetylene (66.1 mg, 805 μmol, 5 equiv.), 45.1 mg of NaOH
(1.13 mmol, 7 equiv.) and 70.0 mg of chloro(1,3-diisopropylbenz-
imidazolin-2-ylidene)gold(I) (161 μmol, 1 equiv.) was dissolved in
15 mL of MeOH and refluxed for four hours. Compound 6 was ob-
tained as a white solid (54.3 mg, 113 μmol, 70 %). Single crystals
suitable for X-ray diffraction were obtained by slow diffusion of
pentane into a solution of compound 6 in acetone. 1H NMR
(400 MHz, [D6]DMSO): δ (ppm) = 7.93 (dd, 3JH-H = 6.2 Hz, 4JH-H =
3.2 Hz, 2H, Har(BzImi)), 7.40 (dd, 3JH-H = 6.2 Hz, 4JH-H = 3.2 Hz, 2H,
Har(BzImi)), 5.35 (hept, 3JH-H = 7.0 Hz, 2H, HCH), 1.67 (d, 3JH-H = 7.0 Hz,
12H, HMe(BzImi)), 1.15 (s, 9H, HMe(alkynyl)). 13C NMR (101 MHz,
[D6]DMSO): δ (ppm) = 191.6, 132.1, 123.9, 115.7, 113.3, 113.1, 55.0,
52.9, 32.3, 27.7, 21.7; elemental analysis calcd. (%) for C19H27N2Au
C 47.50, H 5.67 N 5.83; found C 47.33 H 5.67 N 5.72.
The general procedure for the synthesis of 1,3-dihydroimidazolylid-
ene-AuI-alkynyl complexes 7–12 is shown in Scheme 4.
Scheme 4. General procedure for the synthesis of complexes 7–12.
Potassium tert-butoxide was dissolved in MeOH and the corre-
sponding alkyne was added and stirred at room temperature for
5 min. Meanwhile, a suspension of the corresponding NHC-AuI-Cl
compound in MeOH was prepared in a separate flask and stirred at
room temperature. The solution containing potassium tert-butoxide
and the alkyne was then added dropwise to the suspension con-
taining the NHC-AuI-Cl compound and stirred at room temperature
overnight. The solution was evaporated to dryness, redissolved in
either DCM or Et2O, filtered through Celite an evaporated to dry-
ness. Compounds 8 and 11 needed additional purification steps,
which are indicated at the corresponding entries.
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(Mes)-AuI-(phenylethynyl) (7): 31.4 mg of potassium tert-butoxide
(279 μmol, 3 equiv.) and 30.7 μL phenylacetylene (28.5 mg,
279 μmol, 3 equiv.) were dissolved in 2 mL of MeOH. In a separate
flask, 50.0 mg of Au(IMes)Cl (93.1 μmol, 1 equiv.) were suspended
in 2 mL of MeOH. After dropwise addition of the first solution to
the second, the resulting solution was stirred at room temperature
for overnight. The solution was evaporated to dryness, redissolved
in Et2O and filtered through Celite. Evaporating the solution to dry-
ness yielded compound 7 as an off-white solid (24.2 mg, 40.1 μmol,
43 %). 1H NMR (400 MHz, [D6]DMSO): δ (ppm) = 7.76 (s, 2H, Har(Imi)),
7.21–7.06 (m, 9H, Har(Mes)/Har(Ph)), 2.35 (s, 6H, HMe), 2.08 (s, 12H, HMe).
13C NMR (101 MHz, [D6]DMSO): δ (ppm) = 87.2, 139.4, 135.5, 135.0,
133.4, 132.3, 131.4, 129.5, 128.6, 126.4, 123.9, 103.8, 21.2, 17.7; ele-
mental analysis calcd. (%) for C29H29N2Au C 57.81, H 4.85 N 4.65;
found C 57.78 H 4.86 N 4.50.
(Mes)-AuI-(naphthylethynyl) (8): 31.4 mg of potassium tert-butox-
ide (279 μmol, 3 equiv.) and 39.7 μL naphthylacetylene (42.5 mg,
279 μmol, 3 equiv.) were dissolved in 2 mL of MeOH. In a separate
flask, 50.0 mg of Au(IMes)Cl (93.1 μmol, 1 equiv.) were suspended
in 2 mL of MeOH. After dropwise addition of the first solution to
the second, the resulting solution was stirred at room temperature
for overnight. The solution was evaporated to dryness, redissolved
in DCM and filtered through Celite. Fractional precipitation with
pentane yielded compound 8 as an off-white solid (19.6 mg,
29.8 μmol, 32 %). Single crystals suitable for X-ray diffraction were
obtained by slow diffusion of pentane into a solution of compound
8 in benzene. 1H NMR (400 MHz, [D6]DMSO): δ (ppm) = 8.19–8.11
(m, 1H, HNaph), 7.86–7.81 (m, 1H, HNaph), 7.77 (s, 2H, Har(Imi)), 7.70–
7.66 (m, 1H, HNaph), 7.50–7.45 (m, 2H, HNaph), 7.37–7.28 (m, 2H,
Har(Mes)), 7.14 (s, 4H, Har(Mes)), 2.34 (s, 6H, HMe), 2.11 (s, 12H, HMe).
13C NMR (101 MHz, [D6]DMSO): δ (ppm) = 186.6, 139.0, 138.5, 135.1,
134.6, 133.1, 132.8, 129.1, 128.1, 126.3, 126.1, 125.6, 123.7, 123.6,
100.9, 30.8, 20.8, 17.4; elemental analysis calcd. (%) for C33H31N2Au:
C 60.74, H 4.79 N 4.29; found C 60.60 H 4.95 N 4.02.
(Mes)-AuI-(tert-butylethynyl) (9): 31.4 mg of potassium tert-butox-
ide (279 μmol, 3 equiv.) and 34.4 μL tert-butylacetylene (23.0 mg,
279 μmol, 3 equiv.) were dissolved in 2 mL of MeOH. In a separate
flask, 50.0 mg of Au(IMes)Cl (93.1 μmol, 1 equiv.) were suspended
in 2 mL of MeOH. After dropwise addition of the first solution to
the second, the resulting solution was stirred at room temperature
for overnight. The solution was evaporated to dryness, redissolved
in Et2O and filtered through Celite. Evaporating the solution to dry-
ness yielded compound 9 as a white solid (45.6 mg, 78.2 μmol,
84 %). Single crystals suitable for X-ray diffraction were obtained by
slow diffusion of pentane into a solution of compound 9 in benz-
ene. 1H NMR (400 MHz, [D6]DMSO): δ (ppm) = (s, 2H, Har(Imi)), 7.10
(m, 4H, Har(Mes)), 2.33 (s, 6H, HMe(Mes)), 2.04 (s, 12H, HMe(Mes)), 0.97 (s,
9H, HMe(alkynyl)). 13C NMR (101 MHz, [D6]DMSO, 298 K): δ (ppm) =
186.6, 139.0, 138.5, 135.1, 134.6, 133.1, 132.8, 129.1, 128.1, 126.3,
126.1, 125.6, 123.7, 123.6, 100.9, 30.8, 20.8, 17.4; elemental analysis
calcd. (%) for C27H33N2Au: C 55.67, H 5.71 N 4.81 Found: C 55.32 H
5.72 N 4.79.
(Dipp)-AuI-(phenylethynyl) (10): 27.1 mg of potassium tert-butox-
ide (242 μmol, 3 equiv.) and 26.5 μL phenylacetylene (24.7 mg,
242 μmol, 3 equiv.) were dissolved in 2 mL of MeOH. In a separate
flask, 50.0 mg of Au(dipp)Cl (80.5 μmol, 1 equiv.) were suspended
in 2 mL of MeOH. After dropwise addition of the first solution to
the second, the resulting solution was stirred at room temperature
for overnight. The solution was evaporated to dryness, redissolved
in Et2O and filtered through Celite. Evaporating the solution to dry-
ness and trituration with pentane yielded compound 10 as a white
solid (29.0 mg, 41.9 μmol, 52 %). 1H NMR (500 MHz, [D6]DMSO,
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298 K): δ (ppm) = 7.90 (s, 2H, Har(Imi)), 7.56 (t, 3J = 7.8 Hz 2H, Har(dipp)),
7.41 (d, 3JH-H = 7.8 Hz, 4H, Har(dipp)), 7.16–7.03 (m, 5H, HPh), 2.54–
2.52 (m, 4H, HCH(iPr)), 1.27 (d, 3JH-H = 6.8 Hz, 12H, HMe(iPr)), 1.20 (d,
3JH-H = 6.8 Hz, 12H, HMe(iPr)). 13C NMR (101 MHz, [D6]DMSO): δ
(ppm) = 188.5, 145.4, 134.3, 132.4, 131.1, 130.4, 128.0, 126.0, 125.9,
124.6, 124.0, 103.3, 28.4, 24.3, 23.5; elemental analysis calcd. (%) for
C35H41N2Au: C 61.22, H 6.02 N 4.08 Found: C 60.99 H 5.98 N 4.00.
(Dipp)-AuI-(naphthylethynyl) (11): 27.1 mg of potassium tert-
butoxide (242 μmol, 3 equiv.) and 34.4 μL naphylacetylene (36.8 mg,
242 μmol, 3 equiv.) were dissolved in 2 mL of MeOH. In a separate
flask, 50.0 mg of Au(dipp)Cl (80.5 μmol, 1 equiv.) were suspended
in 2 mL of MeOH. After dropwise addition of the first solution to
the second, the resulting solution was stirred at room temperature
for overnight. The solution was evaporated to dryness, redissolved
in DCM and filtered through Celite. Fractional precipitation with
pentane yielded compound 11 as a white solid (16.3 mg, 21.8 μmol,
27 %). 1H NMR (400 MHz, [D6]DMSO): δ (ppm) = 8.12–8.07 (m, 1H,
HNaph), 7.96 (s, 2H, Har(Imi)), 7.84–7.80 (m, 1H, HNaph), 7.69–7.64 (m,
1H, HNaph), 7.60–7.55 (m, 2H, Har(dipp)), 7.46–7.41 (m, 6H, Har(dipp)),
7.31–7.28 (m, 2H, HNaph), 2.56 (hept, 3JH-H = 6.8 Hz, 4H, HCH(iPr)), 1.34
(d, 3JH-H = 6.8 Hz, 12H, HMe(iPr)), 1.23 (d, 3JH-H = 6.8 Hz, 12H, HMe(iPr)).
13C NMR (101 MHz, [D6]DMSO): δ (ppm) = 188.5, 145.4, 138.3, 134.3,
133.2, 132.8, 130.4, 128.8, 128.1, 126.2, 126.0, 125.5, 124.7, 124.0,
123.7, 109.6, 101.0, 28.4, 24.3, 23.6; elemental analysis calcd. (%) for
C39H43N2Au: C 63.58, H 5.88 N 3.80; found C 63.63 H 5.90 N 3.77.
(Dipp)-AuI-(tert-butylethynyl) (12): 27.1 mg of potassium tert-
butoxide (242 μmol, 3 equiv.) and 29.8 μL tert-butylacetylene
(19.8 mg, 242 μmol, 3 equiv.) were dissolved in 2 mL of MeOH. In
a separate flask, 50.0 mg of Au(dipp)Cl (80.5 μmol, 1 equiv.) were
suspended in 2 mL of MeOH. After dropwise addition of the first
solution to the second, the resulting solution was stirred at room
temperature for overnight. The solution was evaporated to dryness,
redissolved in Et2O and filtered through Celite. Evaporating the so-
lution to dryness yielded compound 12 as a white solid (42.4 mg,
63.6 μmol, 79 %). 1H NMR (400 MHz, [D6]DMSO): δ (ppm) = 7.87 (s,
2H, Har(Imi)), 7.55 (t, 3JH-H = 7.8 Hz, 2H, Har(dipp)), 7.41 (d, 3JH-H =
7.8 Hz, 4H, Har(dipp)), 2.54–2.52 (m, 4H, HCH(iPr)), 1.26 (d, 3JH-H =
6.9 Hz, 12H, HMe(iPr)), 1.19 (d, 3JH-H = 6.9 Hz, 12H, HMe(iPr)), 0.96 (s,
9H, HMe(alkynyl)). 13C NMR (101 MHz, [D6]DMSO): δ (ppm) = 189.4,
145.3, 134.5, 130.3, 124.5, 124.0, 116.0, 111.4, 32.2, 28.4, 27.4, 24.3,
23.5; elemental analysis calcd. (%) for C33H45N2Au: C 59.45, H 6.80
N 4.20; found C 59.37 H 6.89 N 4.25.
Single Crystal X-ray Diffraction
Data were collected on a single-crystal X-ray diffractometer
equipped with a CMOS detector (Photon 100), a rotating anode TXS
and a Helios mirror optic using the APEX3 software package (2, 6,
8 and 9) or a single-crystal X-ray diffractometer equipped with a
CMOS detector (Bruker APEX III, κ-CMOS), an IMS microsource with
Mo-Kα radiation (λ = 0.71073 Å) and a Helios optic using the APEX3
software package(5).[34] Measurements were performed on single
crystals coated with perfluorinated ether. The crystals were fixed on
top of a kapton micro sampler and frozen under a stream of cold
nitrogen. A matrix scan was used to determine the initial lattice
parameters. Reflections were corrected for Lorentz and polarisation
effects, scan speed, and background using SAINT.[35] Absorption
correction, including odd and even ordered spherical harmonics
was performed using SADABS or TWINABS.[36] Space group assign-
ment was based upon systematic absences, E statistics, and success-
ful refinement of the structure. The structures were solved using
SHELXS or SHELXT with the aid of successive difference Fourier
maps, and were refined against all data using SHELXL in conjunc-
tion with SHELXLE.[37,38] Hydrogen atoms were calculated in ideal
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positions as follows: Methyl hydrogen atoms were refined as part
of rigid rotating groups, with a C–H distance of 0.98 Å and Uiso(H) =
1.5·Ueq(C). Other H atoms were placed in calculated positions and
refined using a riding model, with methylene and aromatic C–H
distances of 0.99 Å and 0.95 Å, respectively, and other C–H distan-
ces of 1.00 Å, all with Uiso(H) = 1.2·Ueq(C). Non-hydrogen atoms were
refined with anisotropic displacement parameters. Full-matrix least-
squares refinements were carried out by minimizing Σw(Fo2 – Fc2)2
with the SHELXL weighting scheme[38] Neutral atom scattering fac-
tors for all atoms and anomalous dispersion corrections for the non-
hydrogen atoms were taken from International Tables for Crystallog-
raphy.[39] A split layer refinement was used for disordered groups
and additional restraints (SHELXL: SIMU, DELU and RIGU) were used,
if necessary. Images of the crystal structures were generated with
PLATON.[40]
CCDC 1955875 (for 2), 1955877 (for 5), 1955879 (for 6), 1955876
(for 8), and 1955878 (for 9) contain the supplementary crystallo-
graphic data for this paper. These data can be obtained free of
charge from The Cambridge Crystallographic Data Centre.
Stability and Reactivity Studies: The stability of compounds 1–
12 in H2O was evaluated by dissolving 6 μmol of the respective
compound in 0.5 mL of [D6]DMSO/D2O (80:20). The reactivity
against EtSH was investigated by dissolving 6 μmol of compounds
1–12 in 0.5 mL of [D6]DMSO and addition of an excess of EtSH
and D2O (approximately 300 μmol each). Dry EtSH was obtained by
fractional distillation of EtSH and drying over molecular sieves (3 Å).
Stability and reactivity were checked by 1H NMR spectroscopy over
several days.
Quantum Mechanical Calculations: Density functional theory
(DFT) computations were carried out using the Gaussian 09 pack-
age. The structures were optimized on the B3LYP level of theory[41]
and employing the def2-SVP basis set.[42] Subsequently, single point
energy calculations were performed on the B3LYP/def2-TZVP[42,43]
and the M062X/def2-TZVP[44] level to ensure comparability of func-
tionals and basis sets. For M062X/def2-TZVP additional single point
energy calculations have been performed in the presence of di-
methyl sulfoxide using a self-consistent reaction field (SCRF).[45] DFT
exploration of potential energy surfaces started from plausible ge-
ometries for separate reactants that were fully geometry optimized
without any constraints and confirmed as minima by harmonic fre-
quency calculation. Relaxed potential energy scans were then per-
formed for several reaction coordinates [Au–S, Au–C(alkynyl), Au–
C(NHC), C(alkynyl)–H(H2O)], from which approximate geometries of
transition states were extracted manually. Several possible reaction
coordinates were tested for each reaction step, from which several
possible transition state geometries were tested. Accurate transition
state geometries were then obtained by optimization of the approx-
imate geometries. All optimized geometries were checked by fre-
quency determination for negative eigenfrequencies, correspond-
ing to the local minima (stable compounds) or the local maxima
(transition states) on the potential energy hypersurfaces. Transition
states were additionally checked by intrinsic reaction coordinate
(IRC) calculations.[46] Those reported in the paper are the ones with
lowest energy that properly connect the required reactants and
products.
UV-Visible Absorption Spectroscopy: UV-Visible absorption spec-
tra to investigate the stability of compounds 1–12 in solution were
recorded on a Cary 60 UV-Vis spectrometer (Agilent Technologies,
Santa Clara, USA). A stock solution of compounds was prepared in
DMSO. An aliquot was diluted to ca. 20 μM in 1 × PBS (pH 7.4), and
the UV-Visible spectra acquired at room temperature over 24 h at
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different intervals (every 15 min during the first hour and every
hour for the remaining 23 h).
FRET DNA Melting Assay: Fluorescence resonance energy transfer
(FRET) experiments were run on an Applied Biosystems® Quantum-
Studio 5 Real-Time PCR thermocycler (Thermo Fisher Scientific, Wal-
tham, USA) equipped with a FAM filter (λex = 492 nm; λem =
516 nm). The thermocycler was set to perform a stepwise increase
of 0.3 °C every 30 s, from 25 °C to 95 °C, and measurements were
acquired after each step.
All the oligonucleotides were purchased from Eurogentec (Belgium)
in HPLC purity grade. The FRET probes used were FAM (6-carboxy-
fluorescein) and TAMRA (6-carboxy-tetramethylrhodamine). The lyo-
philized fluorolabelled hTelo (21-mer), d[GGG(TTAGGG)3], C-KIT1,
d[GGGAGGGCGCTGGGAGGAGGG] oligonucleotides were firstly di-
luted in deionized water to obtain 100 μM stock solutions. Stock
solutions were diluted to a concentration of 400 nM in potassium
cacodylate buffer (60 mM, pH 7.4), and then annealed to form G-
quadruplex (G4) structures by heating to 95 °C for 5 min, followed
by cooling to room temperature overnight. Experiments were car-
ried out in a 96-well plate with a total volume of 30 μL. The final
concentration of the G4-oligonucleotide was set to 200 nM in potas-
sium cacodylate buffer (60 mM, pH 7.4). Stock solutions of the gold
compounds in DMSO (1 mM) were freshly prepared prior to the
experiments. The stock solutions were further diluted to a final con-
centration of 2 μM (with a total percentage of DMSO of approx.
0.1 %) in potassium cacodylate buffer (60 mM, pH 7.4) to achieve
G4/gold compound stoichiometry of 1:5.
Cell Lines and Culture Maintenance: The human cancer cell lines
corresponding to breast carcinoma (MCF-7), ovarian adenocarci-
noma (SKOV-3) and skin malignant melanoma (A375) were obtained
from the ATCC. The SKOV-3 and A375 cells were cultured in Dul-
becco's Modified Eagle Medium (DMEM, 4.5 g/L glucose, Corning),
supplemented with 10 % fetal bovine serum (One-Shot FBS, EU-
approved South American Origin, Thermo Fisher Scientific) and 1 %
penicillin/streptomycin (Gibco). MCF-7 cells were grown in Roswell
Park Memorial Institute medium (RPMI, L-glutamine, Corning), sup-
plemented with 10 % fetal bovine serum (One Shot FBS, EU-ap-
proved South American Origin, Thermo Fisher Scientific) and 1 %
penicillin/streptomycin (Gibco). All cell lines were cultured at 37 °C,
in a humidified atmosphere of 5 % CO2 and passage diluted upon
reaching confluence.
Antiproliferative Assays: To evaluate the inhibition of cell growth
by the gold complexes, cells were seeded in 96-well tissue culture-
treated plates (Corning) at 8′000 cells/well in 200 μL complete me-
dium. Working solutions of the gold compounds were prepared in
the required concentration by diluting freshly prepared stock solu-
tions (10–2 M in DMSO) in complete medium. The stock solutions
were protected from light in order to avoid potential light-induced
degradation. Cells were allowed to adhere for 24 h. Then, the me-
dium was refreshed and cells were incubated for 72 h in 200 μL
complete medium containing different concentrations of the gold
compounds. The antiproliferative effects of complexes were evalu-
ated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. Following 72 h exposure, the medium was
removed and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT, Fluorochem) in 10 × PBS (Corning) was added to the
cells, at a final concentration of 0.3 mg/mL. After 3–4 h incubation
at 37 °C and 5 % CO2, the supernatant was discarded and the forma-
zan crystals were dissolved with DMSO. The optical density was
quantified in quadruplicates for each experiment at 550 nm using
a multi-well plate reader (VICTOR X, Perking Elmer). The EC50 value
for each compound in both assays was calculated as the concentra-
Eur. J. Inorg. Chem. 0000, 0–0 www.eurjic.org © 0000 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim11
tion showing 50 % decrease in cell growth, when compared to con-
trols, using a nonlinear fitting. Data is presented as mean ± standard
deviation of at least three independent experiments.
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